Journal of International Oncology››2020,Vol. 47››Issue (8): 505-507.doi:10.3760/cma.j.cn371439-20191031-00066
• Case Report •Previous ArticlesNext Articles
Received:2019-10-31Revised:2020-05-10Online:2020-08-08Published:2020-10-22
"
"
| [1] | Lu S, Yu Y, Yang Y. Retrospect and prospect for lung cancer in China: clinical advances of immune checkpoint inhibitors[J]. Oncologist, 2019,24(Suppl 1):S21-S30. DOI: 10.1634/theoncologist.2019-IO-S1-s02. doi:10.1634/theoncologist.2019-IO-S1-s02pmid:30819828 |
| [2] | Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi:10.3322/caac.21492pmid:30207593 |
| [3] | 段建春, 吴梅娜, 赵军, 等. 培美曲塞联合铂类药物一线治疗晚期非小细胞肺癌的疗效及预测因素分析[J]. 中华结核和呼吸杂志, 2012,35(2):97-101. DOI: 10.3760/cma.j.issn.1001-0939.2012.02.008. doi:10.3760/cma.j.issn.1001-0939.2012.02.008 |
| [4] | Jiang SY, Zhang J, Wang MZ, et al. Small-cell lung cancer transformation in patients with pulmonary denocarcinoma: a case report and review of literature[J]. Medicine Baltimore, 2016,95(6):e2752. DOI: 10.1097/MD.0000000000002752. doi:10.1097/MD.0000000000002752pmid:26871823 |
| [5] | Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations[J]. Cancer Res, 2008, 68(22): 9479-9487. DOI: 10.1158/0008-5472.CAN-08-1643. doi:10.1158/0008-5472.CAN-08-1643pmid:19010923 |
| [6] | Oser MG, Niederst MJ, Sequist LV, et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin[J]. Lancet Oncol, 2015,16(4):e165-e172. DOI: 10.1016/S1470-2045(14)71180-5. doi:10.1016/S1470-2045(14)71180-5pmid:25846096 |
| [7] | Mainardi S, Mijimolle N, Francoz S, et al. Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma[J]. Proc Natl Acad Sci U S A, 2014,111(1):255-260. DOI: 10.1073/pnas.1320383110. doi:10.1073/pnas.1320383110pmid:24367082 |
| [8] | Sutherland KD, Song JY, Kwon MC, et al. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma[J]. Proc Natl Acad Sci U S A, 2014,111(13):4952-4957. DOI: 10.1073/pnas.1319963111. doi:10.1073/pnas.1319963111 |
| [9] | Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Sci Signal, 2013,6(269): p l1. DOI: 10.1126/scisignal.2004088. |
| [10] | Tan HL, Sood A, Rahimi HA, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma[J]. Clin Cancer Res, 2014,20(4):890-903. DOI: 10.1158/1078-0432.CCR-13-1982. doi:10.1158/1078-0432.CCR-13-1982pmid:24323898 |
| [11] | Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo clinic experience[J]. Cancer, 2005,103(6):1172-1178. DOI: 10.1002/cncr.20903. doi:10.1002/cncr.20903pmid:15700264 |
| [12] | Jacks T, Fazeli A, Schmitt EM, et al. Effects of an Rb mutation in the mouse[J]. Nature, 1992,359(6393):295-300. DOI: 10.1038/359295a0. doi:10.1038/359295a0pmid:1406933 |
| [13] | Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer[J]. Nat Commun, 2015,6:6377. DOI: 10.1038/ncomms7377. doi:10.1038/ncomms7377pmid:25758528 |
| [14] | Meder L, König K, Ozreti'c L, et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas[J]. Int J Cancer, 2016,138(4):927-938. DOI: 10.1002/ijc.29835. doi:10.1002/ijc.29835pmid:26340530 |
| [15] | Zakowski MF, Ladanyi M, Kris MG, et al. EGFR mutations in small-cell lung cancers in patients who have never smoked[J]. N Engl J Med, 2006,355(2):213-215. DOI: 10.1056/NEJMc053610. pmid:16837691 |
| [16] | Desai TJ, Brownfield DG, Krasnow MA. Alveolar progenitor and stem cells in lung development, renewal and cancer[J]. Nature, 2014,507(7491):190-194. DOI: 10.1038/nature12930. pmid:24499815 |
| [17] | Miettinen PJ, Warburton D, Bu D, et al. Impaired lung branching morphogenesis in the absence of functional EGF receptor[J]. Dev Biol, 1997,186(2):224-236. DOI: 10.1006/dbio.1997.8593. doi:10.1006/dbio.1997.8593pmid:9205141 |
| [18] | Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors[J]. Sci Transl Med, 2011,3(75):75ra26. DOI: 10.1126/scitranslmed.3002003. doi:10.1126/scitranslmed.3002003pmid:21430269 |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
